Category: Press Release

The Woodlands, Texas and Miami, FL,  July 29, 2025 – Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO) and CellVax Therapeutics Inc., a privately held clinical-stage biotechnology company focused on individualized cell-based immunotherapies, today announced a partnership expansion upon prior work on FK-PC101 – currently in a Phase II clinical trial

Initial patient dosed at comprehensive cancer center City of Hope as Phase 2 trial prepares to expand to additional premier oncology centers nationwide HOUSTON, July 22, 2025 — Diakonos Oncology Corp., a clinical-stage biotechnology company developing a new generation of immunotherapies to treat challenging and aggressive cancers, today announced that the first patient has been

HOUSTON, June 17, 2025 (GLOBE NEWSWIRE) — Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced a collaboration with Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), for current good manufacturing practice (cGMP) manufacturing of MT-601, Marker’s lead

Collaboration Leverages the OPTF01 product to Drive Next-Generation CAR-T Development The Woodlands, Texas and Ehime, Japan, May 8, 2025/ Cision / – Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), and Optieum Biotechnologies (Optieum), a preclinical stage company dedicated to the discovery and development of innovative Chimeric Antigen Receptor (CAR) T

Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), today announced the appointment of Brett Reynolds as its new Chief Financial Officer, effective immediately. Mr. Reynolds has over 25 years of experience in financial leadership roles, primarily in the life sciences industry, and succeeds Tim Heher, who recently retired from the Company.

The Woodlands and Dallas, Texas, January 22, 2025/ Cision / – Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), and Secretome Therapeutics, a biotechnology company advancing therapies derived from neonatal cardiac progenitor cells (nCPCs), today announced a partnership for cGMP manufacturing of Secretome Therapeutic’s lead asset STM-01. Under this partnership, Cellipont

BARLEV, ISRAEL, AND THE WOODLANDS, TEXAS — JANUARY 12, 2025 — ADVA Biotechnology and Cellipont Bioservices are proud to announce their participation at Advanced Therapies Week 2025, taking place in Dallas, Texas, from January 20–23, 2025. Together, they will present a showcase study highlighting how their collaboration successfully transitioned a CAR-T process from a complex manual

The Woodlands, Texas and Muskego, Wisconsin, December 10, 2024/ Cision / – Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), and Xiogenix, an innovator in biopharmaceutical technology, are pleased to announce a strategic partnership. This collaboration enables Cellipont Bioservices to offer its clients access to the state-of-the-art Ares™ X20 fill and

The Woodlands and Houston, Texas, October 8, 2024/ Cision / – Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), and Mongoose Bio, a private clinical-stage biopharmaceutical company pioneering next generation precision T-cell based therapies targeting solid cancers, today announced the signing of an agreement for the Technology Transfer, Process Development, and